We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 79

Competition Bureau sets out preliminary views on patent agreement settlement enforcement
  • Stikeman Elliott LLP
  • Canada
  • October 27 2014

On September 23, 2014, John Pecman, the Commissioner of Competition, delivered the keynote address at the George Mason University Pharma Conference


B.C. Court dismisses proposed class action against generic manufacturers of fentanyl patch
  • Stikeman Elliott LLP
  • Canada
  • July 8 2014

On June 20, 2014, Justice Bracken of the British Columbia Supreme Court dismissed a proposed class action against two generic manufacturers of


Court of Appeal clarifies - for utility the promise of the patent must be "clear and unambiguous"
  • Stikeman Elliott LLP
  • Canada
  • August 21 2013

On July 24, 2013, the Federal Court of Appeal (FCA) issued its decision in Apotex Inc. v. Sanofi-Aventis, overturning a Federal Court decision


Apotex denied damages for the delay it experienced in bringing its generic version of the medicine lovastatin to market
  • Stikeman Elliott LLP
  • Canada
  • February 7 2011

In a recent decision in Apotex Inc. v. Merck & Co., Inc., 2010 FC 1264, the Federal Court denied Apotex damages resulting from the delay it experienced in bringing its generic version of the drug lovastatin to market as a result of Merck’s prohibition application


Federal Court finds Apotex infringed Merck's product-by-process patent for lovastatin
  • Stikeman Elliott LLP
  • Canada
  • February 4 2011

In Merck & Co. Inc. v. Apotex Inc., the Federal Court found Apotex to have infringed Merck’s Canadian Patent No. 1,161,380 (‘380 Patent), a product-by-process patent for the medicine lovastatin


Federal Court of Appeal refuses a patent to a compound already the subject matter of product-by-process patent
  • Stikeman Elliott LLP
  • Canada
  • December 2 2010

On October 20, the Federal Court of Appeal put an end to the disparity in the jurisprudence surrounding whether a patentee could obtain a patent to a medicine subsequent to obtaining a patent to a process for producing the medicine by dismissing Bayer’s appeal in the case of Bayer Schering Pharma Aktiengesellschaft v. The Attorney General of Canada


Government seeks feedback on new drug safety initiatives
  • Stikeman Elliott LLP
  • Canada
  • May 6 2015

As previously reported, the Food and Drugs Act (the Act) has been substantively amended by Bill C-17, also known as Vanessa's Law; the Bill received


Bill C-17 (Vanessa’s Law) receives third reading
  • Stikeman Elliott LLP
  • Canada
  • October 24 2014

Bill C-17, An Act to Amend the Foods and Drugs Act (Vanessa's Law) has proceeded through the committee process without amendment and was read for a


Health Canada releases guidance on “danger to human health or safety” posed by consumer products
  • Stikeman Elliott LLP
  • Canada
  • December 20 2013

Health Canada has released a guidance document on factors it will consider when determining whether a consumer product poses a "danger to human


Health and environmental claims an ongoing bureau focus
  • Stikeman Elliott LLP
  • Canada
  • December 18 2007

Investigations and enforcement actions over marketing and advertising claims related to health products and services have been a significant part of the Bureau's recent fair-business-practices work